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One of the most exciting avenues of translational research today
is determining how to program ab T cells of the immune system to
treat diseases such as cancer. The main function of T cells is the
surveillance of unhealthy cells throughout the body. Because of
their specificity, function, and lasting memory, T cells can
contribute to the prevention and treatment of many diseases.
Two approaches that are being explored to improve T cell
responses using different vaccine methods are adoptive cell
therapies, in which T cells are expanded and possibly manipulated
ex vivo and then reintroduced into the patients [1], and
stimulation of the endogenous T cell repertoire [2]. Both hold
promise for antigen-specific treatments of diseases.
The TCR–Peptide–MHC Interaction
The specificity of the interaction of T cells with their targets is
provided by the T cell receptor (TCR). A limitless number of
different receptors are generated by somatic recombination during
T cell development [3]. Each T cell develops a unique receptor
sequence, which can interact specifically with different targets.
The consequence of this interaction depends on many events that
take place during T cell development. In addition to the TCRs,
the T cells express co-receptors that also interact with the target
cells. Traditionally, T cells that express the cluster of differenti-
ation (CD) 8 co-receptors are cytotoxic, and T cells that express
the CD4 co-receptors help to orchestrate the immune response by
either activating or dampening the response of other immune cells.
The molecular target of the TCR is a peptide antigen bound to
an antigen-presenting molecule found on the surface of most cells
in the body that is known as a major histocompatibility complex
(MHC) molecule. The peptide sits in the MHC molecule like a
hotdog in a bun so that the surface of the peptide-MHC complex
is available for interactions with TCRs [4,5]. Self proteins,
mutated or oncogenic proteins, or pathogen-derived proteins are
processed and cleaved into short peptides. The peptides derived
from proteins normally found inside the cell are conventionally
presented to CD8+ T cells by MHC class I molecules, and those
engulfed from the extracellular milieu are conventionally present-
ed to CD4+ T cells by MHC class II molecules.
The TCR–peptide–MHC interaction leads to a spectrum of T
cell responses. Immature T cells that interact with MHC
molecules are selected for further maturation during positive and
negative selection in the thymus [6,7]. Those that are strongly
reactive towards self antigens are eliminated during negative
selection. T cells that are not negatively selected, but interact with
high affinity ligands may develop into regulatory T cells, which
suppress immune responses [8]. The remaining pool of T cells
interact with peptide-MHC molecules during an immune
response, triggering signals that are propagated though the TCR
into the cell and leading to cell division. The fate of T cells
depends on the strength of the interactions and the surrounding
environment. For example, a number of studies using CD4+ TCR
transgenic T cells show that when the sensitivity of the TCR for an
antigen is changed, the cytokines produced by the T cells also
change [9,10]. Thus, how well T cells interact with target cells and
the conditions under which they interact are both important.
The TCR–Peptide–MHC Interaction in Basic
Immunology
Different, non-mutually exclusive models developed in the last
15 years help describe the optimal affinity of the TCR–peptide–
MHC interaction. The kinetic-proofreading model proposes that
T cells cannot be fully activated unless the TCR–peptide–MHC
interaction remains engaged long enough for the necessary
signaling events to take place [11]. Another model is the serial-
triggering model, in which one peptide–MHC complex binds
multiple TCRs to amplify and sustain signaling by the T cell [12].
A third model predicts that there is an upper and lower limit to the
half-life of binding, or the dwell-time, of the TCR–peptide–MHC
interaction, which narrows the range of affinities that lead to
productive interactions [13]. In addition, the CD8 and CD4 co-
receptors may augment [14] or inhibit [15] the apparent affinity of
the TCR–peptide–MHC interaction. Recent results published by
Huppa et al. have examined the TCR–peptide–MHC interaction
on cells rather than as proteins in solution [16]. They show that
the CD4 co-receptor engagement does not contribute to the
physical association, but is required for optimal signaling into the
T cell. The affinity of many TCR-peptide-MHC interactions has
been determined without co-receptor binding, and most natural
TCRs fall in the 1–200 mM range [17,18]. These affinities are
weaker than many other protein–protein interactions: antibody–
antigen interactions are usually in the nanomolar range, whereas
avidin–biotin affinity is in the femtomolar range. What, then, is the
‘‘ideal’’ affinity for TCRs, and can it be manipulated to optimize
therapeutic immune responses?
The TCR–Peptide–MHC Interaction in the Potency
of Vaccines
Significant interest lies in understanding the optimal affinity
range in the TCR–peptide–MHC interaction for vaccine design.
The strength of this interaction, in addition to the other factors
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of the T cell response. Research by Emily Corse and colleagues,
published in this issue of PLoS Biology, used a simple system to
determine the affinity range that activates T cells by vaccination
(Figure 1). They used a panel of four related peptides that bind to a
mouse MHC class II molecule [19] and CD4+ T cells from a TCR
transgenic mouse [9]. Using standard methods to determine the
binding affinity of TCR–peptide–MHC interactions, they show
that the affinity of these peptides varies across the group. Although
the two highest affinity peptides bind similarly when comparing the
monomeric interaction by surface plasmon resonance, they differ
significantly when comparing the intensity of staining with
multivalent ligands (i.e., staining with MHC tetramers). Although
determining the monomeric interaction provides the relative
binding properties, generally multimeric binding is more physio-
logically relevant because there are numerous interactions between
two cells. The other two peptides are weaker in both assays. The
hierarchy of in vitro stimulation of cognate T cells with these
peptides correlates with the affinity values.
Surprisingly, this correlation is no longer maintained when the
peptides are evaluated in a vaccination setting in vivo. The
responses to the highest affinity peptide are blunted relative to the
intermediate-affinity peptides. The T cells activated by the high-
affinity peptide proliferate less and make less cytokine (IFNc and
IL-2), and fewer of the responding T cells express activation
markers (pAkt and pStat-3). Finally, the T cells activated by the
highest affinity peptide express less of the PD-1 molecule, a marker
of T cell exhaustion.
Occam’s razor presumes that the stronger the TCR–peptide–
MHC interaction, the stronger the T cell response. In fact, unlike
the Corse paper, a previous study by Zehn et al. concluded
precisely that [20]. In a similarly clean experimental system, Zehn
et al. tested a panel of six related peptides that bind to the mouse
MHC class I molecule and CD8+ T cells from a TCR transgenic
mouse. In these experiments, the T cells were transferred into a
syngenic mouse, and the mice were challenged with Listeria
monocytogenes expressing the different peptides. Unlike the Corse
study, the proliferation of the T cells correlated directly with the
affinity of the TCR–peptide–MHC interaction in vitro and in vivo.
What might cause this discrepancy? These two papers use
different model systems; Corse et al. used CD4+ T cells and the
TCR–peptide–MHC interaction had an affinity range from 42.4
to 165 mM. Zehn et al. used CD8+ T cells and the affinity of the
TCR–peptide–MHC interaction was greater than 5.9 mM [21].
The panel of peptides analyzed by Corse et al. had affinities higher
and lower than the cognate peptide in that study. The cognate
peptide in Zehn’s study was at the top of the affinity spectrum, and
since they did not analyze peptides of higher affinity, it is possible
that the cognate peptide falls in the intermediate range. In
addition, the authors measure different outcomes. Because the
route and method of vaccination differed, other aspects of the
milieu may contribute to the differences, TCR down-regulation
may be alternatively regulated, the kinetics of other binding
interactions may be involved, or the induction of cell death may
differ. Finally, the peptides chosen for each TCR may not cover
the entire range of affinities required to produce similar outcomes.
Thus, it may be possible that a peptide of relative intermediate
affinity may best stimulate T cells using the particular conditions in
the Corse study, but until this topic is better investigated it is
unclear if all peptides will follow the same model.
Our own lab also analyzed a panel of peptides with a range of
affinities to determine which peptides generate the most effective
antitumor immunity. As in the studies above, we found that the in
vitro functions of antigen-specific CD8+ T cells correlate with the
TCR–peptide–MHC binding affinity [22]. However, similar to the
Corse study, we observed that the highestaffinitypeptides are not as
effective at eliciting antitumor responses as the intermediate affinity
peptides.However, intheseexperimentsweexamined the naturalT
Table 1. Some factors that influence the strength of T cell responses.
T cell-related factors Interactions between T cells and antigen presenting cells
N Affinity of the T cell receptor-peptide-MHC interaction
N Co-receptor binding
N Co-stimulatory and checkpoint molecule interactions
N Adhesion molecule interactions
N T cell receptor expression
Repertoire and precursor frequency of reactive T cells as a result of positive and negative selection
T cell receptor down-regulation, internalization, or degradation
Intrinsic T cell signaling/kinase and phosphatase activity
Activation-induced cell death of the T cell
Primary vs. memory response
Antigen-related factors Structure/landscape/available contact points for the T cell receptor
Presentation of peptide by MHC molecules/peptide-MHC affinity
Processing of peptides/immunodominance
Binding register of the peptide within the MHC molecule
Dose/concentration/density of peptide
Extrinsic factors Adjuvant used during T cell priming
Regulatory T cells and other peripheral tolerance mechanisms
Cytokine milieu
Nutrient and metabolite availability
doi:10.1371/journal.pbio.1000482.t001
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transferred cells. The repertoire of T cells that respond to each of
the peptides is different, which makes the corresponding affinity
difficult to evaluate. In addition, when we vaccinated mice with the
high-affinity peptides, we obtained different results in the presence
and absence of the tumor, suggesting that the tumor environment is
also influencing the response [23].
Increasing the Affinity of the Interaction by
Mutating the TCR
A number of studies have proceeded on the assumption that
increasing the affinity of the TCR–peptide–MHC interaction
improves T cell immunity. An alternative approach to changing
the peptide, as mentioned above, is to genetically increase the
affinity of the TCR for tumor antigens rather than changing the
antigen. High-affinity tumor–antigen-specific TCRs have been
generated previously by screening phage display libraries, and it
was found that the changes in the TCR were focused on regions
that interact with both the MHC molecule and the antigenic
peptide [24]. These results show that as the affinity of the TCRs
increases into the pM range, the TCRs become more specific for
the MHC molecule, and less specific for the peptide [25]. The
functional consequence of losing peptide specificity is that many
different peripheral antigens may activate these T cells, which
could lead to indiscriminant killing of innocent or healthy cells.
Another group used a similar in vitro evolution method to increase
the affinity of a TCR for its cognate antigen and focused the
changes in the region of the receptor that interacts with the
peptide [26]. This TCR paradoxically had reduced antigen
specificity in the presence of the CD8 co-receptor, highlighting the
potential influence of co-receptor molecules in the strength of the
TCR–peptide–MHC interaction [27].
How then do cells find the right balance (the ‘‘Goldilocks’’ level)
between high- and low-affinity interactions? It is likely that the
many factors that influence the T cell response in vivo after
interaction with a high-affinity ligand are involved. These factors
may provide ‘‘peripheral negative selection’’ to potentially protect
the host from promiscuous T cells that may otherwise be highly
auto-reactive. Toward understanding this possibility and resolving
the conflicting findings of studies in different systems, it would be
interesting to determine if the blunted high-affinity interactions
identified by Corse et al. focused more on the MHC molecule than
the peptide and to determine what other changes are taking place
to the T cell and surrounding environment. In conclusion, T cells
may only naturally function in a narrow range of affinities under
most conditions to ensure optimal responses against foreign
pathogens and minimal responses against auto-antigens, and there
is much yet to be learned about the complex factors that influence
TCR–peptide–MHC interactions and their downstream conse-
quences.
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